Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
Quantum computers process information using quantum bits, or qubits, based on fragile, short-lived quantum mechanical states. To make qubits robust and tailor them for applications, researchers from the Department of Energy’s Oak Ridge National Laboratory sought to create a new material system.
In June, ORNL hit a milestone not seen in more than three decades: producing a production-quality amount of plutonium-238
The Exascale Small Modular Reactor effort, or ExaSMR, is a software stack developed over seven years under the Department of Energy’s Exascale Computing Project to produce the highest-resolution simulations of nuclear reactor systems to date. Now, ExaSMR has been nominated for a 2023 Gordon Bell Prize by the Association for Computing Machinery and is one of six finalists for the annual award, which honors outstanding achievements in high-performance computing from a variety of scientific domains.
Cadet Elyse Wages, a rising junior at the United States Air Force Academy, visited ORNL with one goal in mind: collect air.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
A new nanoscience study led by a researcher at ORNL takes a big-picture look at how scientists study materials at the smallest scales.
Rose Montgomery, a distinguished researcher and leader of the Used Fuel and Nuclear Material Disposition group at ORNL, has been selected to participate in the U.S. WIN Nuclear Executives of Tomorrow, or NEXT, class of 2023 to 2024.
Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.
A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.
After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.